- GlaxoSmithKline (NYSE:GSK) has confessed to a more than decade-old scandal in which staff were caught bribing Chinese officials.
- The admission does not fare well for the company which is also involved in a similar current lawsuit - accused of bribing doctors and officials to boost drug sales in China.
- The DOJ is presently investigating the recent allegations. If a pattern is found, the Justice Department will likely take a tough stance towards the company.